id: topiramate_treatment_to_alcohol_consumption_reduction
name: Topiramate Pharmacotherapy â†’ Reduction in Heavy Alcohol Consumption
from_node:
  node_id: topiramate_treatment
  node_name: Topiramate Pharmacotherapy
to_node:
  node_id: alcohol_consumption_reduction
  node_name: Reduction in Heavy Alcohol Consumption
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Topiramate modulates glutamate and GABA neurotransmitter systems involved
  in alcohol reinforcement'
- 'Step 2: Medication reduces neurobiological reward pathways associated with alcohol
  consumption'
- 'Step 3: Reduced reinforcement leads to decreased number of standard drinks per
  drinking day'
- 'Step 4: Sustained reduction in drinking contributes to improved alcohol use disorder
  outcomes'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Kirsten C Morley et al. 2024. "Topiramate Versus Naltrexone for
    Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled
    Trial.." *American Journal of Psychiatry*. https://doi.org/10.1176/appi.ajp.20230666'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.664158'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: rs2832407_polymorphism
  direction: weakens
  strength: weak
  description: GRIK1 polymorphism rs2832407 showed no effect on topiramate treatment
    response, contrary to prior hypotheses
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/topiramate_treatment_to_alcohol_consumption_reduction.yaml
_category: healthcare_access
